GNRH1 and prostate carcinoma: In a prior study among men with prostate cancer from Sweden, we compared relative excess mortality between those using ADT vs not using ADT between two time periods—during the first wave of the COVID‐19 pandemic (March‐June 2020) and the corresponding months in 2015 to 2019,37 and found no difference, including in analyses stratified by use of gonadotropin‐releasing hormone (GnRH) or bicalutamide monotherapy.